Human α1-proteinase inhibitor (Respreeza®) in α1-antitrypsin deficiency emphysema: a profile of its use in the EU

Autor: Hannah A. Blair

Publikováno v: Drugs & Therapy Perspectives. 35:363-368

Augmentation therapy with human α1-proteinase inhibitor (Respreeza®) is an effective and generally well tolerated treatment option for patients with severe α1-antitrypsin deficiency. In the 2-year RAPID trial, intravenous Respreeza 60 mg/kg once w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da5fd4d9daef7114a7e8895c17c74c76
https://doi.org/10.1007/s40267-019-00648-2

Epidemiological correlation between COVID-19 epidemic and prevalence of α-1 antitrypsin deficiency in the world

Autor: Hiroshi Yoshikura

Publikováno v: Glob Health Med

Among 68 countries in the world, severity of the COVID-19 epidemic was correlated with the prevalence of α-1 antitrypsin (AAT) deficiency. For the severe variant, PI*Z, the correlation coefficient (CC) was 0.8584 for the number of patients and 0.871

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9060163bd3726b63a5597cb65caea0dd
https://europepmc.org/articles/PMC8071687/

Long-term safety of α-1 antitrypsin therapy in children and adolescents with Type 1 diabetes

Autor: Naomi Weintrob, Yael Lebenthal, Avivit Brener, Marianna Rachmiel, Hagar Interator, Neta Loewenthal, Avital Leshem, Orit Horesh, Shlomit Shalitin

Publikováno v: Immunotherapy. 10:1137-1148

Promising findings of α-1 antitrypsin (AAT) intervention in mice models of Type 1 diabetes (T1D) led researchers to investigate AAT as a therapeutic modality for β-cell preservation in recent-onset T1D patients. Our prospective, open-label Phase I/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb7e8c992c71042563efed87a1745db8
https://doi.org/10.2217/imt-2018-0047

Ethylene carbodiimide-fixed donor splenocytes combined with α-1 antitrypsin induce indefinite donor-specific protection to mice cardiac allografts

Autor: Shuangjin Yu, Longhui Qiu, Yi Zhao, Xingqiang Lai, Jin Zhang, Chang Wang, Lizhong Chen, Fen Ning, Guodong Chen

Publikováno v: Transplant International. 30:305-317

Summary Peritransplant infusion of ethylene carbodiimide-fixed donor splenocytes (ECDI-SPs) induces protection of islet and cardiac allografts. However, pro-inflammatory cytokine production during the peritransplantation period may negate the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::902e206e3018b129f782eb1d8ed91315
https://doi.org/10.1111/tri.12903

Exploiting the Disialyl Galactose Activity of α2,6-Sialyltransferase from Photobacterium damselae To Generate a Highly Sialylated Recombinant α-1-Antitrypsin

Autor: Christopher J. Gray, Say-Kong Ng, Pauline M. Rudd, Kun Huang, Sabine L. Flitsch, Matthew S F Choo, Terry Nguyen-Khuong, Wen-Qin Tang, Jien-Nee Tai, Andrea Marchesi, Dawn Leong, Peter Both, Edward Pallister

Publikováno v: Pallister, E G, Choo, M S F, Tai, J, Leong, D S Z, Tang, W, Ng, S, Huang, K, Marchesi, A, Both, P, Gray, C, Rudd, P M, Flitsch, S L & Nguyen-khuong, T 2019, ' Exploiting the Disialyl Galactose Activity of α2,6-Sialyltransferase from Photobacterium damselae To Generate a Highly Sialylated Recombinant α-1-Antitrypsin ', Biochemistry . https://doi.org/10.1021/acs.biochem.9b00563

Sialic acids are sugars present in many animal glycoproteins and are of particular interest in biopharmaceuticals, where a lack of sialylation can reduce bioactivity. Here, we describe how α-2,6-sialyltransferase from Photobacterium damselae can be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042dc84e9b3d4e9cfcb7677cdfd80503
https://pure.manchester.ac.uk/ws/files/140427922/Updated_mauscript_biochemistry_Edward_Pallitser_2nd_revision_manu2.pdf